PL3095484T3 - Mimetyki kalcytoniny do leczenia chorób i zaburzeń - Google Patents

Mimetyki kalcytoniny do leczenia chorób i zaburzeń

Info

Publication number
PL3095484T3
PL3095484T3 PL16174260T PL16174260T PL3095484T3 PL 3095484 T3 PL3095484 T3 PL 3095484T3 PL 16174260 T PL16174260 T PL 16174260T PL 16174260 T PL16174260 T PL 16174260T PL 3095484 T3 PL3095484 T3 PL 3095484T3
Authority
PL
Poland
Prior art keywords
disorders
treating diseases
calcitonin mimetics
calcitonin
mimetics
Prior art date
Application number
PL16174260T
Other languages
English (en)
Inventor
Nozer M. Mehta
William Stern
Amy M. Sturmer
Morten Asser Karsdal
Kim Henriksen
Original Assignee
Keybioscience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keybioscience Ag filed Critical Keybioscience Ag
Publication of PL3095484T3 publication Critical patent/PL3095484T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/585Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL16174260T 2011-11-02 2012-11-02 Mimetyki kalcytoniny do leczenia chorób i zaburzeń PL3095484T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161554771P 2011-11-02 2011-11-02
US201161578620P 2011-12-21 2011-12-21
EP16174260.6A EP3095484B1 (en) 2011-11-02 2012-11-02 Calcitonin mimetics for treating diseases and disorders
EP12846423.7A EP2773365B1 (en) 2011-11-02 2012-11-02 Peptide analogs for treating diseases and disorders

Publications (1)

Publication Number Publication Date
PL3095484T3 true PL3095484T3 (pl) 2018-10-31

Family

ID=51266018

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16174260T PL3095484T3 (pl) 2011-11-02 2012-11-02 Mimetyki kalcytoniny do leczenia chorób i zaburzeń

Country Status (12)

Country Link
EP (3) EP2773365B1 (pl)
CY (1) CY1120332T1 (pl)
DK (2) DK2773365T3 (pl)
ES (2) ES2673617T3 (pl)
HR (1) HRP20180903T1 (pl)
HU (1) HUE039105T2 (pl)
LT (1) LT3095484T (pl)
PL (1) PL3095484T3 (pl)
PT (1) PT3095484T (pl)
RS (1) RS57519B1 (pl)
SI (1) SI3095484T1 (pl)
TR (1) TR201808456T4 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201704429D0 (en) * 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US4764589A (en) * 1987-05-26 1988-08-16 Rorer Pharmaceutical Corporation [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DK2088188T3 (da) 1997-04-16 2012-01-02 Unigene Lab Inc Direkte ekspression af peptider i dyrkningsmedier
AU1574900A (en) 1998-12-04 2000-06-26 Provalis (Uk) Limited Pharmaceutical compositions containing insulin
IL145546A0 (en) 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
ES2496102T3 (es) 2003-03-28 2014-09-18 Sigmoid Pharma Limited Forma de dosificación oral sólida que contiene microcápsulas sin fisuras
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
ES2436152T3 (es) 2003-07-23 2013-12-27 Novartis Ag Uso de calcitonina en osteoartritis
JP2007523050A (ja) 2003-09-17 2007-08-16 カイアズマ・リミテッド 生物学的障壁を通した透過を容易にすることのできる組成物
CN101035547A (zh) 2004-07-22 2007-09-12 蒂奥迈里克斯研究与指导有限公司 含巯基化合物作为流出泵抑制剂的用途
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
CA2613471C (en) 2005-06-24 2016-09-06 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
DK1834635T3 (da) 2006-03-13 2011-10-24 Advancell Advanced In Vitro Cell Technologies S A Stabile nanokapselsystemer til administrtion af aktive molekyler
CN105232482A (zh) 2006-04-07 2016-01-13 默里昂研究Iii有限公司 包含增强剂的固体口服剂型
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
BRPI1006943A2 (pt) * 2009-01-22 2021-06-15 Unigene Laboratories Inc. peptídeo, composição farmacêutica que compreende o peptídeo e método para supressão do apetite, prevenção ou tratamento de uma condição de sobrepeso ou obesidade, ou para tratar diabetes
US20120046224A1 (en) * 2009-03-12 2012-02-23 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome

Also Published As

Publication number Publication date
DK2773365T3 (en) 2016-08-29
EP3357540A1 (en) 2018-08-08
EP3095484A1 (en) 2016-11-23
LT3095484T (lt) 2018-08-10
EP2773365A1 (en) 2014-09-10
CY1120332T1 (el) 2019-07-10
DK3095484T3 (en) 2018-06-25
SI3095484T1 (en) 2018-08-31
EP3095484B1 (en) 2018-05-02
HRP20180903T1 (hr) 2018-08-24
HUE039105T2 (hu) 2018-12-28
EP2773365A4 (en) 2015-05-20
PT3095484T (pt) 2018-06-20
EP2773365B1 (en) 2016-07-20
ES2673617T3 (es) 2018-06-25
TR201808456T4 (tr) 2018-07-23
ES2586805T3 (es) 2016-10-19
RS57519B1 (sr) 2018-10-31

Similar Documents

Publication Publication Date Title
HRP20190356T1 (hr) Mimetici kalcitonina za liječenje bolesti i poremećaja
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
KR102297388B9 (ko) 대사장애를 치료하기 위한 아커만시아의 용도
ZA201500561B (en) Compositions and treatment for eye diseases and disorders
ZA201502290B (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and ist associated disorders
ZA201504065B (en) Therapeutic agent for keratoconjunctive disorders
ZA201308176B (en) Therapeutic treatment
LT3095484T (lt) Kalcitonino mimetikai, skirti ligų ir sutrikimų gydymui
GB201217330D0 (en) Therapeutic for treating inflammatory lung disorders
EP2531186A4 (en) TREATMENT OF HAIR DRESSES
GB201320112D0 (en) Calcitonin Mimetics for treating diseases and disorders
GB201101183D0 (en) Treatment of neurodegenerative disorders
GB201118065D0 (en) Treatment of movement disorders
GB201115761D0 (en) Therapeutic treatments
GB201115759D0 (en) Therapeutic treatments
GB201102222D0 (en) Inventions and therapy
GB201102215D0 (en) Inventions and therapy
GB201102208D0 (en) Inventions and therapy
GB201102210D0 (en) Inventions and therapy
GB201102212D0 (en) Inventions and therapy
GB201102213D0 (en) Inventions and therapy
GB201102216D0 (en) Inventions and therapy
GB201102226D0 (en) Inventions and therapy
GB201102221D0 (en) Inventions and therapy